NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Update

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the target of a significant drop in short interest in the month of February. As of February 13th, there was short interest totaling 392,037 shares, a drop of 30.0% from the January 29th total of 559,856 shares. Based on an average trading volume of 152,582 shares, the days-to-cover ratio is presently 2.6 days. Based on an average trading volume of 152,582 shares, the days-to-cover ratio is presently 2.6 days.

NeuroSense Therapeutics Stock Performance

NRSN stock traded down $0.06 during midday trading on Monday, hitting $0.85. The company had a trading volume of 105,153 shares, compared to its average volume of 167,019. NeuroSense Therapeutics has a 52 week low of $0.68 and a 52 week high of $2.60. The stock’s 50 day moving average price is $0.92 and its 200 day moving average price is $1.05.

Analyst Upgrades and Downgrades

NRSN has been the subject of several research reports. D. Boral Capital restated a “buy” rating and set a $14.00 price target on shares of NeuroSense Therapeutics in a research report on Monday, December 22nd. Wall Street Zen raised NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Hedge Funds Weigh In On NeuroSense Therapeutics

A number of hedge funds have recently modified their holdings of NRSN. Jane Street Group LLC bought a new position in shares of NeuroSense Therapeutics during the second quarter valued at about $54,000. Squarepoint Ops LLC raised its position in NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares during the last quarter. Two Sigma Investments LP purchased a new stake in NeuroSense Therapeutics in the 3rd quarter worth approximately $26,000. Finally, Yorkville Advisors Global LP bought a new stake in shares of NeuroSense Therapeutics in the 4th quarter worth approximately $77,000. Hedge funds and other institutional investors own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.